Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
Commentaries

Heparanase Shakes Hands With Lipoprotein Lipase: A Tale of Two Cells

  1. Subrata Chakrabarti⇑
  1. Department of Pathology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
  1. Corresponding author: Subrata Chakrabarti, subrata.chakrabarti{at}lhsc.on.ca.
Diabetes 2014 Aug; 63(8): 2600-2602. https://doi.org/10.2337/db14-0503
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Altered metabolism with excess provision of lipid substrates may be a major pathogenetic factor linking diabetes with cardiovascular disease—lipoprotein lipase (LPL) being one facilitator of such a process (1,2). Hyperlipidemia, by itself, plays a major role in lipid-provoked cardiovascular pathologies, largely mediated through LPL (3). Under physiological state, due to their presence on the endothelial cell surface, LPLs break down triglyceride lipoproteins in the circulation and provide tissues, like heart and skeletal muscle, with the required fatty acid substrates to derive ATP (3,4). A large volume of data, using genetically manipulated animal models and clinical studies, has found that LPL homeostasis is required for normal cardiac metabolism and function (5,6). In diabetes, increased metabolic demand of the heart is met by the breakdown of fatty acids by coronary LPL. LPL is produced by cardiomyocytes, which need endothelial-derived heparanase for LPL production. In this issue, Wang et al. (7) demonstrated that endothelial heparanase is taken up by the cardiomyocytes through caveolae and is converted to an active form in the lysosomal compartments of these cells. Endothelium-derived heparanase is instrumental for cleaving and releasing LPL from the heparan sulfate proteoglycans on the cardiomyocyte cell surface. Activated heparanase further translocates in the nucleus, increases histone acetylation, and augments matrix metalloproteinase-9 (MMP-9) production. Although this is an adaptive mechanism, increased MMP-9 may act as a mediator of lipotoxicity in chronic diabetes. To this extent, the authors show that MMP-9 cleaves the myocyte surface proteoglycan, syndecan-1. This is a key finding that explains how a vicious cycle of events is stimulated following endothelial exposure to hyperglycemia and thus turning on an endothelial−cardiomyocyte cross talk through the mediation of heparanase.

Earlier studies in this area were focused on the transcription of LPL gene and regulation of this protein in the cardiac tissue in metabolic stress (8). Only in the past decade has interest grown in the mechanism of LPL shuttling from cardiomyocytes to the endothelial barrier surface, where it performs triglyceride breakdown. The same group has previously shown that there was an increased occupancy of LPL on the capillary endothelial cells in streptozotocin-induced diabetic animals (2). However, the exact signaling mechanism, which pushes LPL from cardiomyocyte to the membrane surface of endothelial cells, was not evident. Earlier studies from this group further showed that activation of AMPK-p38 MAP kinase leading to heat-shock protein 25 (Hsp25) phosphorylation and F-actin polymerization plays a role in recruiting LPL from cardiomyocyte inner side to the membrane surface (9). They further demonstrated the process of vesicular fission from the Golgi bodies, where the mature enzyme is emitted (10). A common target for both the processes was found to be Hsp25 (9,10). Phosphorylation of Hsp25 detaches it from protein kinase C δ (PKCδ); the dissociated PKCδ activates downstream molecule protein kinase D, with subsequent stimulation of vesicular fission of LPL and transport to the membrane surface (10).

Although information on how a cardiomyocyte surface LPL could reach the endothelial surface remained a mystery, several consequences of heparanase release were identified. Wang et al. (11) previously showed that the active form of heparanase, derived from the endothelial cells, helps in cleaving and releasing LPL from the heparin sulfate proteoglycans on cardiomyocyte cell surface, whereas the inactive form serves in bringing the intracellular LPL pool to the membrane surface following RhoA activation. Active heparanase also was found to release vascular endothelial growth factor (VEGF) from the same proteoglycan holder (12). The released VEGF may stimulate an autocrine signaling by signaling through VEGF receptors present on the cardiomyocyte cell surface, turning on the AMPK-p38 MAP kinase pathway and rearranging cytoskeleton to propagate the LPL vesicles from inside of cardiomyocyte to the outer membrane (12). Wang et al. (7) showed that heparanase augments cellular transcriptional machinery through increased histone acetyl transferase (HAT) activity (Fig. 1). However, the exact mechanism of how such a process stimulates HAT activity needs further characterization. This study further suggests that endoglycosidase heparanase could be a potential therapeutic target in diabetes-induced cardiovascular diseases. Interestingly, the heparanase inhibitor, PI-88, in NOD mice (a model of type 1 diabetes) prevents reactive oxygen species generation and destruction of islet heparan sulfate (13).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

A diagrammatic outline of the mechanism of endothelial-derived heparanase-mediated regulation of cardiomyocyte lipid uptake and toxicity. Metabolic defect in hyperglycemia starts cross talk between neighboring endothelial cells and cardiomyocytes through the release of an endoglycosidase called heparanase. Heparanase cleaves the cardiomyocyte surface inhabiting heparan sulfate proteoglycans (HSPG), thus releasing LPL and VEGF. This released VEGF turns on VEGF receptor signaling, and through the mediation of p38MAP kinase-Hsp25 and cytoskeletal rearrangement, it stimulates the membrane translocation of LPL. Latent heparanase gets inside the cardiomyocytes and gets activated to active form by a lysosomal-mediated pathway. This active heparanase enters the nucleus and increases transcription of other matrix proteinases, like MMP-9, through augmented HAT activity. MMP-9 cleaves (dashed line) the cell surface matrix component, perhaps allowing syndecan-1 to alter the structural integrity. It is also possible that other cells, e.g., fibroblasts, vascular smooth muscle cells, also may contribute to such cell-to-cell communication. A-HS, active heparanase; L-HS, latent heparanase; VEGFR, VEGF receptor.

The majority, if not all, of chronic diabetes complications is triggered by glucose-induced damage to the endothelial cells (14). However, the effects of hyperglycemia-mediated endothelial abnormalities causing cellular changes may be organ-specific, possibly dictated by cellular constituents and functions peculiar to the specific organ. Wang et al. (7) explain how a cycle of events is initiated by hyperglycemia and turns on an endothelial−cardiomyocyte cross talk. The authors have raised additional interesting scientific questions; e.g., Are similar mechanisms important in long-term diabetes? Is this mechanism also important in type 2 diabetes? We need additional carefully designed studies to answer these questions. Nevertheless, data from this study suggest that targeting endothelial cells may be a rational approach for the development of adjuvant therapy for diabetic cardiovascular complications.

Amid these advancements in knowledge we still face some challenges as cardiomyocytes are also neighbored by cells like vascular smooth muscle cells, fibroblasts, monocytes, and even adipose tissue. It would be really tough to differentiate and compartmentalize the contributions of these cell types as they are also known to secrete growth factors, reactive oxygen/nitrogen species, cytokines, and proteinases. A better understanding of how these different cell types communicate in normal physiology and various pathologies would help us in repairing the miscommunication and developing specific treatments for chronic diabetes complications.

Article Information

Acknowledgments. The author thanks Dr. P. Puthanveetil, Pathology Department, Western University, for help with preparing the manuscript.

Funding. This work was partially funded by Heart and Stroke Foundation of Canada (grant G-13-0003041).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 2643.

  • © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Yagyu H,
    2. Chen G,
    3. Yokoyama M,
    4. et al
    . Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003;111:419–426pmid:12569168
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Pulinilkunnil T,
    2. Abrahani A,
    3. Varghese J,
    4. et al
    . Evidence for rapid “metabolic switching” through lipoprotein lipase occupation of endothelial-binding sites. J Mol Cell Cardiol 2003;35:1093–1103pmid:12967632
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Pillarisetti S,
    2. Saxena U
    . Lipoprotein lipase as a therapeutic target for dyslipidemia. Front Biosci 2003;8:d238–d241pmid:12456348
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wang H,
    2. Eckel RH
    . Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009;297:E271–E288pmid:19318514
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Augustus A,
    2. Yagyu H,
    3. Haemmerle G,
    4. et al
    . Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem 2004;279:25050–25057pmid:15028738
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Yokoyama M,
    2. Seo T,
    3. Park T,
    4. et al
    . Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J Lipid Res 2007;48:646–655pmid:17189607
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Wang Y,
    2. Chiu AP-L,
    3. Neumaier K,
    4. et al
    . Endothelial cell heparanase taken up by cardiomyocytes regulates lipoprotein lipase transfer to the coronary lumen after diabetes. Diabetes 2014;63:2643–2655pmid:24608441
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Ong JM,
    2. Simsolo RB,
    3. Saghizadeh M,
    4. Goers JW,
    5. Kern PA
    . Effects of exercise training and feeding on lipoprotein lipase gene expression in adipose tissue, heart, and skeletal muscle of the rat. Metabolism 1995;44:1596–1605pmid:8786730
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Kim MS,
    2. Kewalramani G,
    3. Puthanveetil P,
    4. et al
    . Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependent actin cytoskeleton organization. Diabetes 2008;57:64–76pmid:17942824
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Kim MS,
    2. Wang F,
    3. Puthanveetil P,
    4. et al
    . Protein kinase D is a key regulator of cardiomyocyte lipoprotein lipase secretion after diabetes. Circ Res 2008;103:252–260pmid:18583709
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Wang Y,
    2. Zhang D,
    3. Chiu AP,
    4. et al
    . Endothelial heparanase regulates heart metabolism by stimulating lipoprotein lipase secretion from cardiomyocytes. Arterioscler Thromb Vasc Biol 2013;33:894–902pmid:23471235
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Zhang D,
    2. Wan A,
    3. Chiu AP,
    4. et al
    . Hyperglycemia-induced secretion of endothelial heparanase stimulates a vascular endothelial growth factor autocrine network in cardiomyocytes that promotes recruitment of lipoprotein lipase. Arterioscler Thromb Vasc Biol 2013;33:2830–2838pmid:24115032
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Ziolkowski AF,
    2. Popp SK,
    3. Freeman C,
    4. Parish CR,
    5. Simeonovic CJ
    . Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes. J Clin Invest 2012;122:132–141pmid:22182841
    OpenUrlCrossRefPubMed
  14. ↵
    1. Brownlee M
    . The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–1625pmid:15919781
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes: 63 (8)

In this Issue

August 2014, 63(8)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Heparanase Shakes Hands With Lipoprotein Lipase: A Tale of Two Cells
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
Heparanase Shakes Hands With Lipoprotein Lipase: A Tale of Two Cells
Subrata Chakrabarti
Diabetes Aug 2014, 63 (8) 2600-2602; DOI: 10.2337/db14-0503

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Heparanase Shakes Hands With Lipoprotein Lipase: A Tale of Two Cells
Subrata Chakrabarti
Diabetes Aug 2014, 63 (8) 2600-2602; DOI: 10.2337/db14-0503
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SRGAP2a: A New Player That Modulates Podocyte Cytoskeleton and Injury in Diabetes
  • Values and Limitations of Targeting lncRNAs in Diabetic Nephropathy
  • A Weighty Matter: Can PUFAs in Pregnancy Prevent Obesity?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2018 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.